Quantcast

Latest Influenza research Stories

2011-02-23 07:30:00

LYON, France and SWIFTWATER, Pa., Feb. 23, 2011 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), today will participate in the first international bell-ringing event by a company listed on NYSE Euronext. The events will acknowledge past successes and future challenges in the battle to eradicate polio at the stock exchanges in New York, Paris, Brussels, Amsterdam and Lisbon. "Sanofi Pasteur stands shoulder to shoulder with...

2011-02-22 03:00:00

BLUE BELL, Pa., Feb. 22, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the company will make presentations at two partnering and scientific conferences: BioPartnering North America Kevin Rassas, Sr. VP, Business Development, will present a corporate overview on Inovio at the 9th Annual BioPartnering North America conference being held in...

2011-02-18 15:27:07

Nasal spray vs. injection -- what would you prefer? Adelaide researchers have taken a step closer to the development of a universal flu vaccine, with results of a recent study showing that a vaccine delivered by a simple nasal spray could provide protection against influenza. University of Adelaide researcher Dr Darren Miller and colleagues have successfully trialled a synthetic universal flu vaccine in mice. The results have appeared this month in a paper in the Journal of General Virology....

2011-02-18 07:00:00

ROCKVILLE, Md., Feb. 18, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biopharmaceutical company, today presented the final safety and immunogenicity results from its 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine clinical trial in Mexico at the invitation-only 7th World Health Organization Meeting (WHO) on Evaluation of Pandemic Influenza Vaccines in Clinical Trials. The meeting was held at the WHO headquarters in Geneva, Switzerland where Dr. Gregory...

2011-02-15 06:00:00

QUEBEC CITY, Feb. 15 /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Ms. Nathalie Landry, Vice President of Product Development, is invited to present at the 7(th) WHO meeting on evaluation of pandemic influenza prototype vaccines in clinical trials. The conference is being held at the World...

2011-02-09 08:00:00

ROCKVILLE, Md., Feb. 9, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Gregory Glenn, Chief Medical Officer of Novavax, will be presenting safety and immunogenicity data from its pivotal 2009 A/H1N1 virus-like particle (VLP) pandemic influenza vaccine clinical trial in Mexico, at the invitation-only 7th WHO Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials. The meeting is being held February 17-18, 2011 at...

2011-02-08 07:44:00

-The Company launches the clinical development of its seasonal flu vaccine- QUEBEC CITY, Feb. 8 /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received Food and Drug Administration ("FDA") clearance for its phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine") clinical trial in the...

2011-02-08 03:00:00

BLUE BELL, Pa., Feb. 8, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. J. Joseph Kim, President and CEO, will present a corporate overview on Inovio at the 13th Annual BIO CEO & Investor conference being held in New York February 14-15, 2011. A live and archived webcast will be accessible on Inovio's website at www.inovio.com....

2011-02-07 03:00:00

BLUE BELL, Pa., Feb. 7, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its new generation DNA vaccine delivery technology, which provides the powerful enabling capabilities of electroporation without contacting the skin, is highlighted in a paper published in the scientific journal Human Vaccines. While current Inovio electroporation devices...

2011-01-11 07:00:00

-Proposed development of a single dose H5N1 influenza vaccine which could be rapidly and widely administered in the case of avian pandemic flu outbreak- -Approved for Public Release, Distribution Unlimited- QUEBEC CITY, Jan. 11 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it was selected to collaborate...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related